Zobrazeno 1 - 10
of 11
pro vyhledávání: ''
Autor:
Joy D. Fisher, Kevin Judy, Alessandro Olivi, Kathryn A. Carson, Mark L. Rosenblum, Jon D. Weingart, Shannon M. Delaney, Stuart A. Grossman, Stephen B. Tatter, M. Eileen Dolan
Publikováno v:
Journal of Clinical Oncology. 25:399-404
Purpose This phase I trial was designed to (1) establish the dose of O6-benzylguanine (O6-BG) administered intravenously as a continuous infusion that suppresses O6-alkylguanine-DNA alkyltransferase (AGT) levels in brain tumors, (2) evaluate the safe
Autor:
Anthony Rodgers, Jørn Herrstedt, Hyman B. Muss, George Klinger, Kevin J. Horgan, Paul J. Hesketh, Norman Bohidar, Richard J. Gralla, Munir Gabriel, David Warr, Franck Skobieranda, Steven M. Grunberg, Carolyn M. Hustad, Harry Raftopoulos, Peter D. Eisenberg
Publikováno v:
Journal of Clinical Oncology. 23:2822-2830
Purpose This is the first study in which the NK1-receptor antagonist, aprepitant (APR), was evaluated for the prevention of chemotherapy-induced nausea and vomiting (CINV) with moderately emetogenic chemotherapy. Patients and Methods Eligible breast
Autor:
Louis Davis, Frank M. Balis, Bharat Damle, Susan Bates, Manish Agrawal, Jame Abraham, Ann Rutt, Brigitte C. Widemann, Herb Kotz, Susan Bakke, Daryl S. Sonnichsen, Tito Fojo, Maureen Edgerly, David Lebwohl
Publikováno v:
Journal of Clinical Oncology. 21:1866-1873
Purpose: The epothilones are a novel class of nontaxane microtubule-stabilizing agents. BMS-247550 is a semisynthetic analog of the natural product epothilone B. We conducted a phase I study administering BMS-247550 as a 1-hour intravenous infusion d
Autor:
S J Houston, A Pecking, I. Resche, K A Harrison, F M Grund, A Bertrand, Eduardo Orihuela, Peter J. Ell, R H Reid, G L Purnell, F R Ahmann, B D Collier, J H McKillop, R A Lerski, F D Thomas, Donald P. Quick, Aldo N. Serafini
Publikováno v:
Journal of Clinical Oncology. 16:1574-1581
PURPOSE To evaluate the effectiveness and safety of samarium-153 (153Sm) lexidronam (EDTMP) in a double-blind, placebo-controlled study. PATIENTS AND METHODS Patients with painful bone metastases secondary to a variety of primary malignancies were ra
Autor:
Mark W. Frazier, Jackie T. Li, Lowell Anthony, Kenneth R. Hande, Wolfgang P. Brade, Dorothy Bush, David H. Johnson, Marshall P. Goren
Publikováno v:
Journal of Clinical Oncology. 16:616-621
PURPOSE To compare the pharmacokinetics of the approved I.V. (intravenous) mesna regimen and an investigational I.V.-oral regimen that could be used in outpatients who receive ifosfamide. PATIENTS AND METHODS The I.V. regimen consisted of three I.V.
Autor:
Mogens Herman Hansen, Per Dombernowsky, B. M. B. Schousboe, Jørn Herrstedt, T.C. Sigsgaard, J. Handberg
Publikováno v:
Journal of Clinical Oncology. 15:1690-1696
PURPOSE To investigate the antiemetic effect and tolerability of the 5-hydroxytryptamine3(5-HT3) antagonist ondansetron plus the dopamine D2 antagonist metopimazine versus ondansetron alone in patients receiving platinum-based chemotherapy. PATIENTS
Autor:
Joseph Kerger, S Lips, E. Tomiak, Dominique de Valeriola, M.J. Piccart, Christophe Ravoet, V Auzannet, Jean-Paul Sculier, Ahmad Awada, Dominique Lossignol
Publikováno v:
Journal of Clinical Oncology. 12:1458-1467
PURPOSE This phase I study of Taxotere (RP 56976, NSC 628503; docetaxel, Rhône-Poulenc Rorer, Antony, France) was undertaken to determine the maximum-tolerated dose (MTD), toxic effects, and basic pharmacokinetics of a day-1 and -8 schedule of this
Autor:
S J Shema, Edwin C. Douglass, Laura C. Bowman, Melissa M. Hudson, Wayne L. Furman, Judith A. Wilimas, Victor M. Santana, John H. Rodman, Neyssa Marina, William H. Meyer
Publikováno v:
Journal of Clinical Oncology. 11:554-560
PURPOSE The tolerance of escalating targeted doses of carboplatin combined with ifosfamide (IFOS)/etoposide (VP-16) (ICE) was assessed in children with recurrent solid tumors. PATIENTS AND METHODS To reduce interpatient variability in carboplatin sys
Autor:
C. B. Stack, S. DelPrete, M. E. Bachinsky, W. Ueno, Richard J. Gralla, R. T. Webb, Paul J. Hesketh, S. L. Silberman, N. L. Dirlam
Publikováno v:
Journal of Clinical Oncology. 17:338-338
PURPOSE: To determine the efficacy and safety of the neurokinin type 1 receptor antagonist CJ-11,974 for the control of high-dose cisplatin-induced emesis. PATIENTS AND METHODS: A double-blind, randomized, phase II design with a group sequential stop
Publikováno v:
Journal of Clinical Oncology. 1:755-762
The pharmacokinetics of intraarterially administered cisplatin (DDP) were studied in three patients with large hepatic tumors, and one patient with a fibrous histiocytoma in the thigh, using an assay sensitive to only those forms of non-protein bound